Inavolisib

A three-drug treatment for advanced breast cancer delays disease progression by 15 months, twice the time of existing therapies, according to a trial involving 325 patients from 28 countries. The combination, including a new drug inavolisib, was found to be more effective than current NHS treatments, potentially transforming outcomes for those with PIK3CA-mutated HR+/HER2- breast cancer.

A three-drug therapy, including palbociclib, inavolisib, and fulvestrant, significantly delays progression of HR+/HER2- breast cancer by 15 months, compared to 7.3 months with a placebo.

A trial found that a combination of three drugs can double survival time for patients with incurable breast cancer, potentially transforming outcomes for many of the 61,000 UK women with advanced breast cancer.

A three-drug therapy for advanced breast cancer potentially doubles time without disease progression, according to a trial published in The New England Journal of Medicine. The combination, including palbociclib, inavolisib, and fulvestrant, delayed progression by 15 months compared to 7.3 months with a placebo. This breakthrough could be transformative for HR+/HER2- breast cancer patients.

A study led by Prof. Nick Turner at the Institute of Cancer Research demonstrates the potential of a three-drug therapy (inavolisib, palbociclib, and fulvestrant) to significantly improve progression-free survival in HR-positive breast cancer with PIK3CA mutations. The combination, already approved by the US FDA, could represent a transformative advance for patients.

October 2024 saw 4 new FDA cancer drug approvals: asciminib for CML, zolbetuximab-clzb for CLDN18.2-positive gastric/GEJ adenocarcinoma, inavolisib plus palbociclib/fulvestrant for PIK3CA-mutant HR+/HER2- breast cancer, and neoadjuvant/adjuvant nivolumab for NSCLC without EGFR/ALK mutations.

Courtney Van Houzen, PharmD, discusses bringing bispecific antibody treatments to community settings, inspired by a patient's need for continuity of care. Promising efficacy and safety of fianlimab and cemiplimab in advanced melanoma is highlighted. Inavolisib plus palbociclib and fulvestrant gains FDA approval for HR+/HER2- PIK3CA-mutated breast cancer. Talazoparib plus enzalutamide shows survival improvement in mCRPC. The TWINPEAK trial initiates with PT886 and pembrolizumab for gastric and GEJ cancers.

RLY-2608, an oral, mutant-selective PI3Kα allosteric inhibitor, addresses off-target toxicities of existing modulators like alpelisib and inavolisib. It is in Phase I for HR+/HER2- breast cancer treatment with fulvestrant.

FDA approves inavolisib plus palbociclib/fulvestrant for endocrine-resistant, PIK3CA-mutated, HR+/HER2– advanced breast cancer; perioperative pembrolizumab improves event-free survival in resected stage III/IVA HNSCC; 2023 cisplatin shortage led to chemotherapy alternatives and cost increases; Yuan Yuan discusses ADC and CDK4/6 inhibitor sequencing in breast cancer; talazoparib plus enzalutamide improves OS in mCRPC.